~~<i id='251537DB26'><strike id='251537DB26'><tt id='251537DB26'><pre id='251537DB26'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

leisure time

author：focus 2025-09-30 17:27:15 - browse：1

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： FDA weighs limits of animal data in assessing artificial wombs

Wikipedia

hotspot

focus

explore

focus

knowledge

AttendeesoftheWorldScoutJamboreepreparetoleaveascoutcampingsiteinBuan,SouthKorea,Tuesday,Aug.8,2023.

WSS

Fed up with FDA, ALS advocates consider a take

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

FDA panel to weigh safety of artificial wombs for preterm births

Democratic lawmaker calls for 'well

knowledge

leisure time

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

'A game

Dobbs anniversary: the lost opportunity of abortion as health care

Trump Jan. 6 attorney John Lauro is ex

Moonlake's readout produced a cash windfall. Risks remain

People with substance use disorder deserve online privacy

Peter Hotez and the public health issue of online harassment

FDA panel to weigh safety of artificial wombs for preterm births

Medicare details structure of new drug price negotiation program

Why the quest to eradicate polio has stumbled

hotspot

How the messy conversation about Dolly changed bioethics

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Information blocking fines are now fair game in health care

What happened to the House vote on health price transparency?

The struggle to figure out which patients 'deserve' Wegovy

focus

explore

focus

knowledge